Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Igor Puzanov et al.|New England Journal of Medicine|2015Cited by 1.7k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upMichel Ducreux, Dirk Arnold, Caroline Caramella et al.|Annals of Oncology|2015Cited by 1.3k
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialÉtienne Garin, Lambros Tselikas, Boris Guiu et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 602
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Josep Tabernero et al.|New England Journal of Medicine|2023Cited by 530
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Takashi Kojima et al.|JAMA Oncology|2018Cited by 518